2018
DOI: 10.1016/j.intimp.2018.10.030
|View full text |Cite
|
Sign up to set email alerts
|

Pretreatment with cathelicidin-BF ameliorates Pseudomonas aeruginosa pneumonia in mice by enhancing NETosis and the autophagy of recruited neutrophils and macrophages

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
21
0
1

Year Published

2019
2019
2024
2024

Publication Types

Select...
8
1

Relationship

1
8

Authors

Journals

citations
Cited by 22 publications
(22 citation statements)
references
References 37 publications
0
21
0
1
Order By: Relevance
“…Alveolar macrophages and neutrophils are the first immune cells in the host innate response to bacterial pathogen infection.34 Our recent work indicated that Cathelicidin-BF , another AMP subtype, enhanced neutrophil extracellular traps, which are the main facilitators of the capture and clearance of bacteria through the activation of innate immunity.35 Other studies have indicated that macrophages also contribute to the clearance of bacterial pathogen infection.36 In this study, our results demonstrated that Tachyplesin III improved alveolar macrophage phagocytosis in a dose-dependent manner in vitro (Figure 5), which may directly reduce the BALF burden (Figure 3C). Thus, our study reports a novel therapeutic strategy for gram-negative MDR bacterial coinfection using the AMP Tachyplesin III .…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Alveolar macrophages and neutrophils are the first immune cells in the host innate response to bacterial pathogen infection.34 Our recent work indicated that Cathelicidin-BF , another AMP subtype, enhanced neutrophil extracellular traps, which are the main facilitators of the capture and clearance of bacteria through the activation of innate immunity.35 Other studies have indicated that macrophages also contribute to the clearance of bacterial pathogen infection.36 In this study, our results demonstrated that Tachyplesin III improved alveolar macrophage phagocytosis in a dose-dependent manner in vitro (Figure 5), which may directly reduce the BALF burden (Figure 3C). Thus, our study reports a novel therapeutic strategy for gram-negative MDR bacterial coinfection using the AMP Tachyplesin III .…”
Section: Discussionmentioning
confidence: 99%
“…The lung tissue histology analysis was performed as previously described.35 Briefly, the left lung tissues were harvested from mice the day after bacterial infection and fixed in 4% paraformaldehyde at room temperature for 24 hrs. Subsequently, the tissues were embedded in paraffin and stained with a hematoxylin and eosin (H & E) kit purchased from Solarbio ® Life Science.…”
Section: Methodsmentioning
confidence: 99%
“…Autophagy not only does actively participate in NET formation but also inhibits the excessive release of NETs. A study of mice infected with Pseudomonas aeruginosa and affected by pneumonia showed that the activation of innate immunity improves the disease outcome via antimicrobial agents that enhance autophagy to rapidly eliminate NETs, thus preventing severe tissue damage [132]. Enhancement of NET generation and release, which requires autophagy, is the key process in antimicrobial treatment, providing evidence of the dual role of autophagy in NETosis.…”
Section: Autophagy Immunity and Virus Infectionmentioning
confidence: 99%
“…Importantly, the microspheres prevented peptide degradation while still maintaining antimicrobial efficacy against E. coli, Shigella dysenteriae, and Salmonella typhi (Bao et al, 2018). In addition, using a murine model of P. aeruginosa pneumonia, intravenous pre-treatment of formulated cathelicidin-BF activated the immune response to improve antibacterial functions while enhancing macrophage clearance and dampening inflammation via obstruction of the NF-κB signaling cascade (Liu et al, 2018). Cathelicidin-BF has also been conjugated to PLGA polymers, resulting in even slower release (up to 30 days) while exhibiting minimal toxicity toward eukaryotic cells as well as low hemolysis (Schlosser et al, 2008).…”
Section: Novel Formulations For Peptide Deliverymentioning
confidence: 99%